No material news briefings were available for AbbVie Inc. in the current reporting cycle. The prior cycle's brief, dated 2026-05-24, referenced AbbVie's trailing twelve-month revenue through 31 March 2026 as the primary data anchor [Brief - 2026-05-24]. The subsequent brief dated 2026-06-01 noted the same foundational data point without additional developments [Brief - 2026-06-01]. This report is grounded in regulatory filings, ownership disclosures, and macroeconomic data as detailed in the sections below.
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, representing year-over-year growth of 12.43%. Net income for the same period was $3.64 billion, producing a net margin of 5.79%. Gross margin was recorded at 67.37% and operating margin at 24.41%. EPS on a year-over-year basis declined 45.83%. The company held $9.39 billion in cash against total debt of $64.50 billion. The reported price-to-earnings ratio was 109.89 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership activity in the most recent 13F reporting period showed material divergence across major filers. Millennium Management (Izzy Englander) added 61% to its position, while Bridgewater Associates (Ray Dalio) increased its holding by 114% [SEC 13F - Bridgewater - Q1 2026]. Conversely, Citadel (Ken Griffin) reduced its position by 11% and AQR Capital (Cliff Asness) reduced its position by 23% [SEC 13F - Citadel - Q1 2026; SEC 13F - AQR Capital - Q1 2026]. No insider transaction data from SEC Form 4 filings was available in the current context window for the reporting period.
The prevailing macroeconomic backdrop shows the 10-year US Treasury yield at 4.55% and the 2-year yield at 4.17%, with the yield curve in a normal configuration [FRED DGS10; FRED DGS2]. The spread of approximately 38 basis points between the two tenors reflects the current shape of the curve as of the generation date.
This report was triggered by material institutional position changes identified in 13F disclosures, specifically the sizeable additions by Millennium Management and Bridgewater Associates alongside reductions from Citadel and AQR Capital, as noted above.